|
1.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2.
|
de Gramont A, Figer A, Seymour M, et al:
Leucovorin and fluorouracil with or without oxaliplatin as
first-line treatment in advanced colorectal cancer. J Clin Oncol.
18:2938–2947. 2000.
|
|
3.
|
Fuchs CS, Marshall J, Mitchell E, et al:
Randomized, controlled trial of irinotecan plus infusional, bolus,
or oral fluoropyrimidines in first-line treatment of metastatic
colorectal cancer: updated results from the BICC-C study. J Clin
Oncol. 25:4779–4786. 2007. View Article : Google Scholar
|
|
4.
|
Goldberg RM, Sargent DJ, Morton RF, et al:
A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar
|
|
5.
|
Chaudhury P, Hassanain M, Bouganim N, et
al: Perioperative chemotherapy with bevacizumab and liver resection
for colorectal cancer liver metastasis. HPB (Oxford). 12:37–42.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Sobrero AF, Maurel J, Fehrenbacher L, et
al: EPIC: phase III trial of cetuximab plus irinotecan after
fluoropyrimidine and oxaliplatin failure in patients with
metastatic colorectal cancer. J Clin Oncol. 26:2311–2319. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Zinser-Sierra JW, Rodríguez-Ramírez S,
Villalobos-Valencia R and Ramírez-Márquez M: Use of bevacizumab in
metastatic colorectal cancer: report from the Mexican opinion and
analysis forum on colorectal cancer treatment with bevacizumab
(September 2009). Drugs R D. 11:101–111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Strickler JH and Hurwitz HI:
Bevacizumab-based therapies in the first-line treatment of
metastatic colorectal cancer. Oncologist. 17:513–524. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Chibaudel B, Tournigand C, André T and de
Gramont A: Therapeutic strategy in unresectable metastatic
colorectal cancer. Ther Adv Med Oncol. 4:75–89. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
De Stefano A, Carlomagno C, Pepe S, et al:
Bevacizumab-related arterial hypertension as a predictive marker in
metastatic colorectal cancer patients. Cancer Chemother Pharmacol.
68:1207–1213. 2011.PubMed/NCBI
|
|
11.
|
Pohl A, El-Khoueiry A, Yang D, et al:
Pharmacogenetic profiling of CD133 is associated with response rate
(RR) and progression-free survival (PFS) in patients with
metastatic colorectal cancer (mCRC), treated with bevacizumab-based
chemotherapy. Pharmacogenomics J. 13:173–180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Sastre J, Maestro ML, Gómez-España A, et
al: Circulating tumor cell count is a prognostic factor in
metastatic colorectal cancer patients receiving first-line
chemotherapy plus bevacizumab: a Spanish Cooperative Group for the
Treatment of Digestive Tumors study. Oncologist. 17:947–955. 2012.
View Article : Google Scholar
|
|
13.
|
Formica V, Palmirotta R, Del Monte G, et
al: Predictive value of VEGF gene polymorphisms for metastatic
colorectal cancer patients receiving first-line treatment including
fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis.
26:143–151. 2011. View Article : Google Scholar
|
|
14.
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
15.
|
Gervaz P, Scholl B, Mainguene C, et al:
Angiogenesis of liver metastases: role of sinusoidal endothelial
cells. Dis Colon Rectum. 43:980–986. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Kabbinavar F, Hurwitz HI, Fehrenbacher L,
et al: Phase II, randomized trial comparing bevacizumab plus
fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with
meta-static colorectal cancer. J Clin Oncol. 21:60–65. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Des Guetz G, Uzzan B, Nicolas P, et al:
Microvessel density and VEGF expression are prognostic factors in
colorectal cancer. Meta-analysis of the literature. Br J Cancer.
94:1823–1832. 2006.PubMed/NCBI
|
|
18.
|
Degirmenci M, Karaca B, Gorumlu G, et al:
Efficacy and safety of bevacizumab plus capecitabine and irinotecan
regimen for metastatic colorectal cancer. Med Oncol. 27:585–591.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Vredenburgh JJ, Desjardins A, Herndon JE
Jr, et al: Bevacizumab plus irinotecan in recurrent glioblastoma
multiforme. J Clin Oncol. 25:4722–4729. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Scartozzi M, Giampieri R, Maccaroni E, et
al: Pre-treatment lactate dehydrogenase levels as predictor of
efficacy of first-line bevacizumab-based therapy in metastatic
colorectal cancer patients. Br J Cancer. 106:799–804. 2012.
View Article : Google Scholar
|
|
23.
|
Hong YS, Cho HJ, Kim SY, et al: Carbonic
anhydrase 9 is a predictive marker of survival benefit from lower
dose of bevacizumab in patients with previously treated metastatic
colorectal cancer. BMC Cancer. 9:2462009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Suenaga M, Matsusaka S, Ueno M, et al:
Predictors of the efficacy of FOLFIRI plus bevacizumab as
second-line treatment in meta-static colorectal cancer patients.
Surg Today. 41:1067–1074. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Formica V, Massara MC, Portarena I, et al:
Role of CA19.9 in predicting bevacizumab efficacy for metastatic
colorectal cancer patients. Cancer Biomark. 5:167–175.
2009.PubMed/NCBI
|
|
26.
|
Guiu B, Petit JM, Bonnetain F, et al:
Visceral fat area is an independent predictive biomarker of outcome
after first-line bevacizumab-based treatment in metastatic
colorectal cancer. Gut. 59:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Budai B, Komlósi V, Adleff V, et al:
Impact of SHMT1 polymorphism on the clinical outcome of patients
with metastatic colorectal cancer treated with first-line
FOLFIRI+bevacizumab. Pharmacogenet Genomics. 22:69–72.
2012.PubMed/NCBI
|
|
28.
|
Abajo A, Rodriguez J, Bitarte N, et al:
Dose-finding study and pharmacogenomic analysis of fixed-rate
infusion of gemcitabine, irinotecan and bevacizumab in pretreated
metastatic colorectal cancer patients. Br J Cancer. 103:1529–1535.
2010. View Article : Google Scholar
|
|
29.
|
Hansen TF, Christensen Rd, Andersen RF, et
al: The predictive value of single nucleotide polymorphisms in the
VEGF system to the efficacy of first-line treatment with
bevacizumab plus chemotherapy in patients with metastatic
colorectal cancer: results from the Nordic ACT trial. Int J
Colorectal Dis. 27:715–720. 2012. View Article : Google Scholar
|
|
30.
|
Colucci G, Gebbia V, Paoletti G, et al
Gruppo Oncologico Dell’Italia Meridionale: Phase III randomized
trial of FOLFIRI versus FOLFOX4 in the treatment of advanced
colorectal cancer: a multicenter study of the Gruppo Oncologico
Dell’Italia Meridionale. J Clin Oncol. 23:4866–4875.
2005.PubMed/NCBI
|
|
31.
|
Abajo A, Boni V, Lopez I, et al:
Identification of predictive circulating biomarkers of
bevacizumab-containing regimen efficacy in pre-treated metastatic
colorectal cancer patients. Br J Cancer. 107:287–290. 2012.
View Article : Google Scholar
|
